BR9915988A - Vacina para peptidase c5a estreptocócica - Google Patents

Vacina para peptidase c5a estreptocócica

Info

Publication number
BR9915988A
BR9915988A BR9915988-0A BR9915988A BR9915988A BR 9915988 A BR9915988 A BR 9915988A BR 9915988 A BR9915988 A BR 9915988A BR 9915988 A BR9915988 A BR 9915988A
Authority
BR
Brazil
Prior art keywords
vaccine
scp
streptococcal
hemolytic
streptococcus
Prior art date
Application number
BR9915988-0A
Other languages
English (en)
Other versions
BRPI9915988B1 (pt
BRPI9915988B8 (pt
Inventor
Paul Patrick Cleary
Deborah K Stafslien
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of BR9915988A publication Critical patent/BR9915988A/pt
Publication of BRPI9915988B1 publication Critical patent/BRPI9915988B1/pt
Publication of BRPI9915988B8 publication Critical patent/BRPI9915988B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Exposure Control For Cameras (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"VACINA PARA PEPTIDASE C5a ESTREPTOCóCICA" Trata-se de novas vacinas para uso contra colonização ou infecção por Streptococcus <225>- hemolítico. As vacinas contém uma quantidade imunogênica de uma variante de peptidase C5a estreptocócica (SCP). Também é descrito um método de proteção de um mamífero susceptível contra colonização ou infecção por Streptococcus <225>- hemolítico por administração como uma vacina. SCP enzimaticamente inativo, e polinucleotídeos codificando proteínas SCP são ainda descritos.
BRPI9915988A 1998-12-07 1999-12-03 vacina para peptidase c5a estreptocócica BRPI9915988B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/206,898 US6355255B1 (en) 1998-12-07 1998-12-07 Streptococcal C5a peptidase vaccine
PCT/US1999/028826 WO2000034487A1 (en) 1998-12-07 1999-12-03 STREPTOCOCCAL C5a PEPTIDASE VACCINE

Publications (3)

Publication Number Publication Date
BR9915988A true BR9915988A (pt) 2001-09-04
BRPI9915988B1 BRPI9915988B1 (pt) 2015-08-18
BRPI9915988B8 BRPI9915988B8 (pt) 2021-05-25

Family

ID=43662233

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915988A BRPI9915988B8 (pt) 1998-12-07 1999-12-03 vacina para peptidase c5a estreptocócica

Country Status (18)

Country Link
US (4) US6355255B1 (pt)
EP (3) EP1892298B1 (pt)
JP (2) JP5122703B2 (pt)
KR (1) KR100777502B1 (pt)
CN (2) CN1679929B (pt)
AT (2) ATE503017T1 (pt)
AU (2) AU779085B2 (pt)
BR (1) BRPI9915988B8 (pt)
CA (1) CA2354508C (pt)
CY (1) CY1106983T1 (pt)
DE (2) DE69943305D1 (pt)
DK (3) DK1892298T3 (pt)
ES (3) ES2401998T3 (pt)
IL (2) IL143289A0 (pt)
MX (1) MXPA01005757A (pt)
PT (3) PT1892298E (pt)
SI (2) SI1892298T1 (pt)
WO (1) WO2000034487A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
SG165981A1 (en) * 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
CA2523358A1 (en) * 2003-04-23 2004-11-04 Hansa Medical Ab Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
WO2006050341A2 (en) * 2004-11-01 2006-05-11 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
GB2428006A (en) * 2005-07-07 2007-01-17 Jevgenis Morov AMI-3 vaccine comprising group A Streptococcus pyogenes bacteria
US7596254B2 (en) * 2006-03-17 2009-09-29 William Marsh Rice University Intra-operative 3-D reconstruction of bone cement boli using X-rays
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008002472A2 (en) * 2006-06-23 2008-01-03 Danisco Us Inc., Genencor Division Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
US20080311129A1 (en) * 2006-11-02 2008-12-18 Camas Incorporated Adherence inhibitor directed to and method of making and using
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
LT2144924T (lt) * 2007-04-16 2016-10-10 Minervax Aps Sulieto baltymo vakcina
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
JP2012508174A (ja) * 2008-11-05 2012-04-05 ワイス・エルエルシー β溶血性連鎖球菌（ＢＨＳ）疾患を予防するための多成分免疫原性組成物
EP3170508B1 (en) 2010-06-04 2019-11-13 Wyeth LLC Vaccine formulations
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102746388B (zh) * 2012-07-02 2014-06-25 中山大学 一种链球菌保护性抗原C5a及其制备方法
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
KR101775093B1 (ko) 2016-05-31 2017-09-19 그린코스 주식회사 베타인살리실레이트와 폴리에틸렌글리콜을 포함하는 각질 용해 화장품 조성물, 그 제조 방법, 및 이를 포함하는 화장품
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.
CN106822885B (zh) * 2017-02-16 2020-06-30 清华大学 肺炎链球菌疫苗
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
CN109045292A (zh) * 2018-11-08 2018-12-21 山东大学 一种a群链球菌寡糖蛋白缀合物及其制备方法与应用
KR102165688B1 (ko) 2020-04-03 2020-10-14 주식회사 퀀타매트릭스 그람 양성균 배양용 배양액
CN118510548A (zh) 2022-01-13 2024-08-16 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152411A (en) * 1977-07-27 1979-05-01 Akzona Incorporated High specific activity labeled substances
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4695562A (en) 1984-04-06 1987-09-22 Univ. Of Tennessee Research Corp. Synthetic peptide compounds
US4772584A (en) 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
EP0272929B1 (en) 1986-12-24 1996-03-20 Genentech, Inc. Enkephalinase for therapeutic use
US5124153A (en) 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5162226A (en) 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US4863159A (en) 1988-03-25 1989-09-05 Morrison Molded Fiber Glass Company Apparatus for use in the exercise of the human body
DE68926427T2 (de) 1988-03-25 1996-12-05 Univ Rockefeller Vom streptococcus m-protein abgeleitete synthetische peptide und damit hergestellte impfstoffe
JP3126381B2 (ja) 1990-07-31 2001-01-22 ジェネンテク，インコーポレイテッド 減少されたクリアランスを有する組織プラスミノーゲンアクチベーター変異体
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
EP0672123A1 (en) 1992-01-08 1995-09-20 The Rockefeller University Multifunctional surface protein of streptococci
EP0632831B1 (en) 1992-03-09 2002-11-27 The Regents Of The University Of California Nucleic acid, expressionvector and compositions for the identification and synthesis of recombinant sialyltransferases
WO1993021220A1 (en) 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
IL106922A (en) 1992-09-14 1998-08-16 Novartis Ag Complex materials with one or more wettable surfaces and a process for their preparation
WO1994006421A1 (en) 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine
ATE211654T1 (de) 1992-09-16 2002-01-15 Univ Tennessee Res Corp Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
US5866135A (en) 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5679654A (en) 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5618129A (en) 1995-03-13 1997-04-08 Paragon Electric Company, Inc. Snap-engaging mounting plate
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist

Also Published As

Publication number Publication date
KR100777502B1 (ko) 2007-11-16
CA2354508C (en) 2011-02-01
PT2308981E (pt) 2013-02-21
PT1137785E (pt) 2007-10-22
WO2000034487A1 (en) 2000-06-15
DK1137785T3 (da) 2007-12-10
DK2308981T3 (da) 2013-05-13
AU2004231164B2 (en) 2008-05-01
BRPI9915988B1 (pt) 2015-08-18
US7635483B2 (en) 2009-12-22
EP2308981A1 (en) 2011-04-13
EP2308981B1 (en) 2013-02-13
EP1892298A1 (en) 2008-02-27
KR20010082326A (ko) 2001-08-29
US20050136068A1 (en) 2005-06-23
EP1137785A1 (en) 2001-10-04
EP1892298B1 (en) 2011-03-23
CN1679929B (zh) 2012-09-26
CA2354508A1 (en) 2000-06-15
PT1892298E (pt) 2011-06-01
BRPI9915988B8 (pt) 2021-05-25
CN1329669A (zh) 2002-01-02
EP1137785B1 (en) 2007-08-15
SI2308981T1 (sl) 2013-04-30
ES2293745T3 (es) 2008-03-16
US6355255B1 (en) 2002-03-12
SI1892298T1 (sl) 2011-08-31
ATE503017T1 (de) 2011-04-15
DE69936877T2 (de) 2008-04-30
CN1679929A (zh) 2005-10-12
JP2012072153A (ja) 2012-04-12
AU779085B2 (en) 2005-01-06
CN100389198C (zh) 2008-05-21
US20060153879A1 (en) 2006-07-13
DE69943305D1 (de) 2011-05-05
CY1106983T1 (el) 2012-09-26
ES2401998T3 (es) 2013-04-26
AU2166500A (en) 2000-06-26
DK1892298T3 (da) 2011-06-14
AU2004231164A1 (en) 2004-12-09
IL143289A0 (en) 2002-04-21
ES2363446T3 (es) 2011-08-04
EP1137785B8 (en) 2007-11-21
MXPA01005757A (es) 2002-04-24
JP5122703B2 (ja) 2013-01-16
JP2002531584A (ja) 2002-09-24
IL143289A (en) 2011-11-30
US8440205B2 (en) 2013-05-14
US20040062777A1 (en) 2004-04-01
ATE370237T1 (de) 2007-09-15
DE69936877D1 (de) 2007-09-27
US6951653B2 (en) 2005-10-04

Similar Documents

Publication Publication Date Title
BR9915988A (pt) Vacina para peptidase c5a estreptocócica
PT877624E (pt) Vacina de c5a peptidase estreptococica
MY129263A (en) Vaccine composition
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
BR9712970A (pt) Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
FI972054A0 (fi) Immunogeenisiä koostumuksia
BR0009663A (pt) Composições de vacinas antibacterianas
ES2192559T3 (es) Vacuna para la proteccion de aves de corral contra la coccidiosis.
DK0775746T3 (da) Vaccine mod fjerkræcoccidiose
DK0682950T3 (da) Slimhindeadministration af pneumokok-antigener
DE69824794D1 (de) Streptococcus equi Impfstoff
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
DE60022995D1 (de) Impfstoff
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
UA67250A (en) Strain bovinae herpesvirus-1 &#34;moldavian&#34; for the preparation of vaccines and diagnosticums
EP0178928A3 (en) Vaccines

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 03/12/2019